NASDAQ
NRBO

Neurobo Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Neurobo Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$0.45
Today's High:
$0.47
Open Price:
$0.459
52W Low:
$0.361
52W High:
$29.88
Prev. Close:
$0.454
Volume:
63261

Company Statistics

Market Cap.:
$17.49 million
Book Value:
0.659
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-37.09%
Return on Equity TTM:
-65.4%

Company Profile

Neurobo Pharmaceuticals Inc had its IPO on 2016-08-05 under the ticker symbol NRBO.

The company operates in the Healthcare sector and Biotechnology industry. Neurobo Pharmaceuticals Inc has a staff strength of 2 employees.

Stock update

Shares of Neurobo Pharmaceuticals Inc opened at $0.46 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.45 - $0.47, and closed at $0.46.

This is a +2.2% increase from the previous day's closing price.

A total volume of 63,261 shares were traded at the close of the day’s session.

In the last one week, shares of Neurobo Pharmaceuticals Inc have increased by +1.98%.

Neurobo Pharmaceuticals Inc's Key Ratios

Neurobo Pharmaceuticals Inc has a market cap of $17.49 million, indicating a price to book ratio of 1.84 and a price to sales ratio of 0.

In the last 12-months Neurobo Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-11646000. The EBITDA ratio measures Neurobo Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Neurobo Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -37.09% with a return of equity of -65.4%.

In Q2, Neurobo Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Neurobo Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-8.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neurobo Pharmaceuticals Inc’s profitability.

Neurobo Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.3325. Its price to sales ratio in the trailing 12-months stood at 0.

Neurobo Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$29.18 million
Total Liabilities
$3.98 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Neurobo Pharmaceuticals Inc ended 2024 with $29.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $29.18 million while shareholder equity stood at $25.20 million.

Neurobo Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $3.98 million in other current liabilities, 38000.00 in common stock, $-99133000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $28.69 million and cash and short-term investments were $28.69 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Neurobo Pharmaceuticals Inc’s total current assets stands at $29.17 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $967000.00 and inventory worth $0.

In 2024, Neurobo Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Neurobo Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.46
52-Week High
$29.88
52-Week Low
$0.361
Analyst Target Price
$6

Neurobo Pharmaceuticals Inc stock is currently trading at $0.46 per share. It touched a 52-week high of $29.88 and a 52-week low of $29.88. Analysts tracking the stock have a 12-month average target price of $6.

Its 50-day moving average was $0.51 and 200-day moving average was $0.71 The short ratio stood at 0.55 indicating a short percent outstanding of 0%.

Around 5018.2% of the company’s stock are held by insiders while 113.5% are held by institutions.

Frequently Asked Questions About Neurobo Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Neurobo Pharmaceuticals Inc is NRBO

The IPO of Neurobo Pharmaceuticals Inc took place on 2016-08-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$125.05
-8.35
-6.26%
$158.4
-3.95
-2.43%
$0.24
0.02
+8.3%
$5.05
-0.27
-5.08%
$28.64
-1.81
-5.95%
$5194.1
-56.9
-1.08%
Andhra Paper Ltd (ANDHRAPAP)
$548.95
-27.6
-4.79%
$0.27
0.02
+7.91%
$3.36
-0.02
-0.59%
$75.08
-4.3
-5.42%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Address

200 Berkeley Street, Boston, MA, United States, 02116